ALX Oncology Q3 net loss improves to $0.41/share; highlights evorpacept benefit in CD47-high gastric cancer

ALX ONCOLOGY HOLDINGS INC

2025-Q3 EPS reported -$1.48

GAAP net loss for Q3 2025 was $22.1M ($0.41/share), improved from $30.7M ($0.58/share) in Q3 2024.
Cash, cash equivalents and investments at Sept 30, 2025: $66.5M; runway into Q1 2027.
ASPEN-06 exploratory analysis: In CD47-high retained HER2+ gastric cancer, evorpacept combo achieved 65.0% ORR vs 26.1% for control; median DOR 25.5 vs 8.4 months.
Phase 1 ALX2004 (EGFR-targeted ADC) cleared first dose cohort; currently enrolling 2 mg/kg dose; initial safety data expected 1H 2026.
Barbara Klencke, M.D., appointed interim Chief Medical Officer; brings 30+ years oncology drug development experience.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.